Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia

References

• Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study [Research Support, Non-U.S. Gov't]. Cancer. 2012;118(15):3793–3800.
   PubMed Web of Science ®Google Scholar
• Nelson S, Boise LH, Kaufman JL, et al. Changing epidemiology and improved survival in patients with Waldenstrom macroglobulinemia: review of Surveillance, Epidemiology, and End Results (SEER) Data. Blood. 2013;122(21):3135–3135.
   Web of Science ®Google Scholar
• Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53(8):1625–1626.
   PubMed Web of Science ®Google Scholar
• Kirkwood MK, Kosty MP, Bajorin DF, et al. Tracking the workforce: the American Society of Clinical Oncology workforce information system. J Oncol Pract. 2013;9(1):3–8.
   PubMedGoogle Scholar
• Forte GJ, Hanley A, Hagerty K, et al. American Society of Clinical Oncology National Census of Oncology Practices: preliminary report. J Oncol Pract. 2013;9(1):9–19.
   PubMedGoogle Scholar
• Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137(6):511–520.
   PubMed Web of Science ®Google Scholar
• Giri S, Pathak R, Aryal MR, et al. Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. Blood. 2015;125(21):3359–3360.
   PubMed Web of Science ®Google Scholar
• Go RS, Bottner WA, Gertz MA. Making the case to study the volume-outcome relationship in hematologic cancers. Mayo Clin Proc. 2015;90(10):1393–1399.
   PubMed Web of Science ®Google Scholar
• Go RS, Bartley AC, Crowson CS, et al. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2017;35(6):598–604.
   PubMed Web of Science ®Google Scholar
• NCDB. National Cancer Data Base 2016. The National Cancer Data Base (NCDB), a joint program of the Commission on Cancer (CoC) of the American College of Surgeons (ACoS) and the American Cancer Society (ACS). [cited 2020 May 22]. Available from: https://www.facs.org/quality-programs/cancer/ncdb.
   Google Scholar
• Go RS, Al-Hamadani M, Shah ND, et al. Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma. Cancer. 2016;122(16):2552–2559.
   PubMed Web of Science ®Google Scholar
• Lauseker M, Hasford J, Pfirrmann M, German CML Study Group, et al. The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood. 2014;123(16):2494–2496.
   PubMed Web of Science ®Google Scholar
• Gruen RL, Pitt V, Green S, et al. The effect of provider case volume on cancer mortality: systematic review and meta-analysis. CA Cancer J Clin. 2009;59(3):192–211.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169(1):81–89.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res. 2005;11(5):1786–1790.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines . Mayo Clin Proc. 2010;85(9):824–833.
   PubMed Web of Science ®Google Scholar
• Klodzinska S, Vos JM, Kersten MJ, et al. A survey on diagnostic methods and treatment strategies used in patients with Waldenstrom's macroglobulinaemia in The Netherlands. Neth J Med. 2013;71(2):90–96.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Kay NE, Rabe KG, et al. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer. 2012;118(7):1827–1837.
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–582.
   PubMed Web of Science ®Google Scholar
• Pan C-C, Kung P-T, Wang Y-H, et al. Effects of multidisciplinary team care on the survival of patients with different stages of non-small cell lung cancer: a national cohort study. PLoS One. 2015;10(5):e0126547.
   PubMed Web of Science ®Google Scholar
• Fennell ML, Das IP, Clauser S, et al. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr. 2010;2010(40):72–80.
   PubMedGoogle Scholar
• DeMartino JK, Larsen JK. Equity in cancer care: pathways, protocols, and guidelines. J Natl Compr Canc Netw. 2012;10 (Suppl 1):S1–S9.
   PubMedGoogle Scholar
• Loberiza FR Jr, Cannon AJ, Weisenburger DD, et al. Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol. 2009;27(32):5376–5382.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res. 2010;34(10):1340–1343.
   PubMed Web of Science ®Google Scholar
• Zanwar S, Abeykoon JP, Kapoor P. Novel treatment strategies in the management of Waldenström macroglobulinemia. Curr Hematol Malig Rep. 2020;15(1):31–43.
   PubMed Web of Science ®Google Scholar